Moderna Inc. (MRNA) Stock

Valuation data is not available for this stock.

With a beta of 1.86, Moderna Inc. is significantly more volatile than the market. For every 10% market move, this stock tends to move 19% in the same direction. Higher beta stocks offer greater potential returns but with increased risk. The price-to-book ratio of 1.04 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Moderna Inc. achieves a profit margin of -105.70%, meaning it retains $-105.70 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -972.00% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -29.30% and ROA at -15.80%, the company achieves moderate returns on invested capital.

Moderna Inc.'s revenue declined by 35.30% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. Earnings decreased by 85.10% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry averages for proper context.

Moderna Inc. has a market capitalization of $10.50B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 386.74M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry, it competes with other firms in this sector.

Moderna Inc.'s book value per share is $26.01, while the current stock price is $31.65, resulting in a price-to-book (P/B) ratio of 1.22. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

27 analysts cover MRNA with 22% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The bearish sentiment could create opportunity if analysts are wrong. The consensus target of $47.59 implies 50.4% upside, but targets are often adjusted to follow price moves rather than predict them.

Current analyst recommendations:1 Strong Buy, 5 Buy, 17 Hold, 1 Sell, 3 Strong Sell. The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

RSI data is not available for this stock.

MACD and moving average data are not available for this stock.